Aardvark Therapeutics Pauses Key Trials Amid Cardiac Safety Concerns
Event summary
- Aardvark Therapeutics voluntarily paused Phase 3 HERO and OLE trials for ARD-101 due to reversible cardiac observations in healthy volunteers.
- ARD-201 obesity program trials also paused pending further guidance expected in Q2 2026.
- Company reported $110.0 million in cash as of December 31, 2025, supporting operations into Q2 2027.
- Clinical and preclinical data from ARD-101 program published in Molecular Metabolism.
- Net loss for 2025 was $57.6 million, up from $20.6 million in 2024.
The big picture
Aardvark Therapeutics' pause of key trials highlights the critical balance between clinical progress and safety concerns in the biopharmaceutical industry. The company's engagement with the FDA and the publication of positive clinical data in Molecular Metabolism underscore the strategic importance of navigating regulatory hurdles while maintaining investor confidence. With a cash runway extending into 2027, the company's ability to sustain operations and resume trials will be closely watched.
What we're watching
- Regulatory Clarity
- Whether the FDA engagement will provide a clear path forward for ARD-101 and ARD-201 programs by Q2 2026.
- Cash Burn Rate
- The pace at which Aardvark Therapeutics will deplete its $110.0 million cash reserves and the potential need for additional funding.
- Clinical Data Impact
- How the published clinical and preclinical data from the ARD-101 program will influence investor and regulatory perceptions.